市場調查報告書

傳染性軟疣(MC)- 市場洞察,流行病學,預測 2028年

Molluscum Contagiosum (MC) Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 918181
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
傳染性軟疣(MC)- 市場洞察,流行病學,預測 2028年 Molluscum Contagiosum (MC) Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的傳染性軟疣(MC)的2017年的患病數估算為1,216萬1,039人,同年的市場規模估算為21億8,343萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的傳染性軟疣(MC)市場相關調查,疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 傳染性軟疣(MC)市場概要

  • 傳染性軟疣(MC)的分佈(實數值)
  • 傳染性軟疣(MC)的分佈(預測值)

第3章 鑰匙摘要

第4章 流行病學與調查手法

第5章 疾病背景:傳染性軟疣(MC)

  • 簡介
  • 病因
  • 症狀
  • 原因
  • 診斷
  • 鑑別診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的傳染性軟疣(MC)的總患病數
  • 美國
    • 假設和理論性根據
    • 傳染性軟疣(MC)的總患病數
    • 傳染性軟疣(MC)的患病數:各年齡
    • 傳染性軟疣(MC)的患病數:性別
  • 歐盟5國
    • 德國
      • 假設和理論性根據
      • 傳染性軟疣(MC)的總患病數
      • 傳染性軟疣(MC)的患病數:各年齡
      • 傳染性軟疣(MC)的患病數:性別
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 假設和理論性根據
    • 傳染性軟疣(MC)的總患病數
    • 傳染性軟疣(MC)的患病數:各年齡
    • 傳染性軟疣(MC)的患病數:性別

第7章 現行治療

第8章 未滿足需求

第8章 案例研究

第9章 新藥

  • VP-102/Cantharidin:Verrica Pharmaceuticals
    • 產品概要
    • 產品開發趨勢
    • 臨床趨勢
    • 安全性和有效性
    • 產品簡介
  • SB206: Novan/Ligand Pharmaceuticals
  • VBP-245: Veloce Biopharma

第10章 市場規模

  • 主要調查結果
  • 主要7個國家的整體市場規模
  • 主要7個國家的市場規模:各治療藥物

第11章 美國市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第12章 歐盟5國市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本市場預測

  • 日本
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 市場成長要素

第15章 市場障礙

第16章 關鍵意見領袖的意見

第17章 附錄

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0747

DelveInsight's "Molluscum Contagiosum (MC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Molluscum Contagiosum (MC), historical and forecasted epidemiology as well as the Molluscum Contagiosum (MC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Molluscum Contagiosum (MC) market report provides current treatment practices, emerging drugs, Molluscum Contagiosum (MC) market share of the individual therapies, current and forecasted Molluscum Contagiosum (MC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Molluscum Contagiosum (MC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Molluscum Contagiosum (MC) Disease Understanding and Treatment Algorithm

The DelveInsight Molluscum Contagiosum (MC) market report gives a thorough understanding of the Molluscum Contagiosum (MC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Molluscum Contagiosum (MC).

Treatment

It covers the details of conventional and current medical therapies available in the Molluscum Contagiosum (MC) market for the treatment of the condition. It also provides Molluscum Contagiosum (MC) treatment algorithms and guidelines in the United States, Europe, and Japan.

Molluscum Contagiosum (MC) Epidemiology

The Molluscum Contagiosum (MC) epidemiology division provide insights about historical and current Molluscum Contagiosum (MC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Molluscum Contagiosum (MC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Molluscum Contagiosum (MC) Epidemiology

The epidemiology segment also provides the Molluscum Contagiosum (MC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Molluscum Contagiosum (MC) Drug Chapters

Drug chapter segment of the Molluscum Contagiosum (MC) report encloses the detailed analysis of Molluscum Contagiosum (MC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Molluscum Contagiosum (MC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Molluscum Contagiosum (MC) treatment.

Molluscum Contagiosum (MC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Molluscum Contagiosum (MC) treatment.

Molluscum Contagiosum (MC) Market Outlook

The Molluscum Contagiosum (MC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Molluscum Contagiosum (MC) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Molluscum Contagiosum (MC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Molluscum Contagiosum (MC) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Molluscum Contagiosum (MC) market in 7MM.

The United States Market Outlook

This section provides the total Molluscum Contagiosum (MC) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Molluscum Contagiosum (MC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Molluscum Contagiosum (MC) market size and market size by therapies in Japan is also mentioned.

Molluscum Contagiosum (MC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Molluscum Contagiosum (MC) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Molluscum Contagiosum (MC) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Molluscum Contagiosum (MC) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Molluscum Contagiosum (MC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Molluscum Contagiosum (MC) emerging therapies.

Reimbursement Scenario in Molluscum Contagiosum (MC)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Molluscum Contagiosum (MC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Molluscum Contagiosum (MC) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Molluscum Contagiosum (MC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Molluscum Contagiosum (MC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Molluscum Contagiosum (MC) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Molluscum Contagiosum (MC) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Molluscum Contagiosum (MC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Molluscum Contagiosum (MC) market

Report Highlights

  • In the coming years, Molluscum Contagiosum (MC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum (MC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Molluscum Contagiosum (MC). Launch of emerging therapies will significantly impact the Molluscum Contagiosum (MC) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Molluscum Contagiosum (MC)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Molluscum Contagiosum (MC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Molluscum Contagiosum (MC) Pipeline Analysis
  • Molluscum Contagiosum (MC) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Molluscum Contagiosum (MC) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Molluscum Contagiosum (MC) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Molluscum Contagiosum (MC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Molluscum Contagiosum (MC) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Molluscum Contagiosum (MC) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Molluscum Contagiosum (MC) market size during the forecast period (2017-2030)?
  • At what CAGR, the Molluscum Contagiosum (MC) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Molluscum Contagiosum (MC) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Molluscum Contagiosum (MC) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Molluscum Contagiosum (MC)?
  • What is the historical Molluscum Contagiosum (MC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Molluscum Contagiosum (MC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Molluscum Contagiosum (MC)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Molluscum Contagiosum (MC) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Molluscum Contagiosum (MC) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Molluscum Contagiosum (MC) in the USA, Europe, and Japan?
  • What are the Molluscum Contagiosum (MC) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Molluscum Contagiosum (MC)?
  • How many therapies are developed by each company for Molluscum Contagiosum (MC) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Molluscum Contagiosum (MC) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Molluscum Contagiosum (MC) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Molluscum Contagiosum (MC) and their status?
  • What are the key designations that have been granted for the emerging therapies for Molluscum Contagiosum (MC)?
  • What are the global historical and forecasted market of Molluscum Contagiosum (MC)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Molluscum Contagiosum (MC) market
  • To understand the future market competition in the Molluscum Contagiosum (MC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Molluscum Contagiosum (MC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Molluscum Contagiosum (MC) market
  • To understand the future market competition in the Molluscum Contagiosum (MC) market

Table of Contents

1. Key Insights

2. Executive Summary of Molluscum Contagiosum (MC)

3. Competitive Intelligence Analysis for Molluscum Contagiosum (MC)

4. Molluscum Contagiosum (MC): Market Overview at a Glance

  • 4.1. Molluscum Contagiosum (MC) Total Market Share (%) Distribution in 2017
  • 4.2. Molluscum Contagiosum (MC) Total Market Share (%) Distribution in 2030

5. Molluscum Contagiosum (MC): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Molluscum Contagiosum (MC) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Molluscum Contagiosum (MC) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Molluscum Contagiosum (MC) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Molluscum Contagiosum (MC) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Molluscum Contagiosum (MC) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Molluscum Contagiosum (MC) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Molluscum Contagiosum (MC) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Molluscum Contagiosum (MC) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Molluscum Contagiosum (MC) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Molluscum Contagiosum (MC) Treatment and Management
  • 8.2. Molluscum Contagiosum (MC) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Molluscum Contagiosum (MC) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Molluscum Contagiosum (MC): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Molluscum Contagiosum (MC) Market Size in 7MM
  • 13.3. Molluscum Contagiosum (MC) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Molluscum Contagiosum (MC) Total Market Size in the United States
    • 15.1.2. Molluscum Contagiosum (MC) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Molluscum Contagiosum (MC) Total Market Size in Germany
    • 15.3.2. Molluscum Contagiosum (MC) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Molluscum Contagiosum (MC) Total Market Size in France
    • 15.4.2. Molluscum Contagiosum (MC) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Molluscum Contagiosum (MC) Total Market Size in Italy
    • 15.5.2. Molluscum Contagiosum (MC) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Molluscum Contagiosum (MC) Total Market Size in Spain
    • 15.6.2. Molluscum Contagiosum (MC) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Molluscum Contagiosum (MC) Total Market Size in the United Kingdom
    • 15.7.2. Molluscum Contagiosum (MC) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Molluscum Contagiosum (MC) Total Market Size in Japan
    • 15.8.3. Molluscum Contagiosum (MC) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Molluscum Contagiosum (MC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Molluscum Contagiosum (MC) Epidemiology (2017-2030)
  • Table 2 : 7MM Molluscum Contagiosum (MC) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Molluscum Contagiosum (MC) Epidemiology in Germany (2017-2030)
  • Table 6 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Molluscum Contagiosum (MC) Epidemiology in France (2017-2030)
  • Table 8 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Molluscum Contagiosum (MC) Epidemiology in Italy (2017-2030)
  • Table 10 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Molluscum Contagiosum (MC) Epidemiology in Spain (2017-2030)
  • Table 12 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Molluscum Contagiosum (MC) Epidemiology in the UK (2017-2030)
  • Table 14 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Molluscum Contagiosum (MC) Epidemiology in Japan (2017-2030)
  • Table 16 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Molluscum Contagiosum (MC) Epidemiology (2017-2030)
  • Figure 2 : 7MM Molluscum Contagiosum (MC) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Molluscum Contagiosum (MC) Epidemiology in the United States (2017-2030)
  • Figure 4 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Molluscum Contagiosum (MC) Epidemiology in Germany (2017-2030)
  • Figure 6 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Molluscum Contagiosum (MC) Epidemiology in France (2017-2030)
  • Figure 8 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Molluscum Contagiosum (MC) Epidemiology in Italy (2017-2030)
  • Figure 10 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Molluscum Contagiosum (MC) Epidemiology in Spain (2017-2030)
  • Figure 12 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Molluscum Contagiosum (MC) Epidemiology in the UK (2017-2030)
  • Figure 14 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Molluscum Contagiosum (MC) Epidemiology in Japan (2017-2030)
  • Figure 16 : Molluscum Contagiosum (MC) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)